Investigators tested a new neoadjuvant immunotherapy to fight prostate cancer using a virus-mimicking drug to activate the immune system.
YD Bio Limited ('YD Bio Ltd” or the 'Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer ...
Bria-IMT demonstrates a median overall survival of 15.6 months, surpassing historical data for heavily pretreated metastatic ...
Unraveling the Subtypes and Functional Roles of Dendritic Cells in Cancer Immunity and Immunotherapy
Dendritic cells (DCs) are central players in cancer immunity, serving as the primary link between innate and adaptive immune responses. Their functional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results